Search clinical trials for: Erythropoiesis

Total 114 results

Assiut University

Not yet recruiting

Prevalence of Erythropoiesis Stimulating Agents Hyporesponsiveness in Dialysis Patients in Assiut University Hospital

Erythropoietin Resistant Anemia (EPO Resistant Anemia)
Yonsei University

Not yet recruiting

The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes

Kidney Failure, Chronic

Korea, Republic of
GlaxoSmithKline

Recruiting

Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P) (ASCEND-P)

Anaemia

United States, Italy, Spain, France, United Kingdom, Korea, Republic of, Netherlands, Japan, Argentina, Belgium, Turkey
Julia Xu
Carnegie Mellon University; American Society of Hematology

Recruiting

Hydroxyurea and EPO in Sickle Cell Disease (ACHiEvE-SCD)

Sickle Cell Disease | Anemia, Sickle Cell

United States, Nigeria
The University of Hong Kong

Recruiting

Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II

Exercise Physiology

Hong Kong
Shenyang Sunshine Pharmaceutical Co., LTD.

Recruiting

Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure

Hemodialysis | Kidney Failure, Chronic

China
Kaohsiung Medical University Chung-Ho Memorial...
National Sun Yat-sen University

Recruiting

Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients (AI)

End Stage Renal Disease on Dialysis

Taiwan
Hospital Son Espases

Recruiting

Paricalcitol Improves Anemia of Inflammation (PIERAID)

Anemia

Spain
University of Utah
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Molecular Biology of Polycythemia and Thrombocytosis

Polycythemia | Thrombocytosis

United States
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Anaemia

United States, Australia, Korea, Republic of, Spain, Taiwan, Bulgaria, Canada, Italy, Russian Federation, Ukraine, Argentina, Belgium, France, Philippines, South Africa, Thailand, Israel, Sweden, Singapore, Czechia, Hong Kong, Net... and more
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Anaemia

United States, Canada, France, Russian Federation, Spain, Australia, United Kingdom, Romania, Brazil, Korea, Republic of, Italy, Poland, Argentina, Mexico
GlaxoSmithKline

Terminated

Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)

Anaemia

United Kingdom
GlaxoSmithKline

Completed

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

Anaemia

United States
Cambridge University Hospitals NHS Foundation Trust
GlaxoSmithKline

Completed

Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease. (OPERA-CKD)

Cardiovascular Diseases | Chronic Kidney Disease

United Kingdom
Akebia Therapeutics

Completed

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Anemia Associated With Chronic Kidney Disease (CKD)

United States
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease (CONVERSION)

Anemia of Chronic Kidney Disease

United States
Gdansk University of Physical Education and Sport

Completed

The Effect of Supplementation of Vitamin D3 on Inflammation Induced by 100 km Running, Iron Metabolism and Erythropoiesis

Healthy | Iron Metabolism | Ineffective Erythropoiesis | Inflammation; Muscle
University of Copenhagen

Completed

Tracing Changed Production of Red Blood Cells

Erythrocytosis | Erythropoiesis Abnormal

Denmark
Helwan University

Completed

Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients

Anemia of Chronic Kidney Disease | Chronic Renal Failure | Chronic Renal Failure Anemia

Egypt
Janssen Research & Development, LLC

Completed

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic Syndromes

United States, Belgium, Italy, Spain, Netherlands, Russian Federation
Akebia Therapeutics
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Anemia

United States, Italy, Spain, Hungary, Czechia, Poland
University of Louisville
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease

Anemia of End Stage Renal Disease

United States
FibroGen
AstraZeneca

Completed

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

Anemia Associated With End Stage Renal Disease (ESRD)

United States
Centre Hospitalier Annecy Genevois

Completed

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis (Ruxo-EPO)

Myelofibrosis; Anemia
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Patient Blood Management In CARdiac sUrgical patientS (ICARUS)

Iron-deficiency | Anemia | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Blood Loss Anemia | Erythropoiesis Abnormal

Italy
Rennes University Hospital

Completed

Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections (SELFEPO)

Renal Insufficiency, Chronic | Organ Graft

France
University of New Mexico
National Center for Research Resources (NCRR)

Completed

Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants

Preterm Infants

United States
University Hospital Tuebingen

Withdrawn

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Type 2 Diabetes Mellitus (T2DM)

Germany
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Anaemia | Aspergillosis, Allergic Bronchopulmonary

Australia, Korea, Republic of, Spain, United States, Taiwan, Bulgaria, Mexico, Ukraine, Argentina, Belgium, South Africa, Singapore, Austria, Canada, Netherlands, Russian Federation, Sweden, Turkey, United Kingdom, Germany, Romania and more
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

CKD Anemia in Stable Dialysis Patients

United States, Puerto Rico
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

Anaemia

United States, Korea, Republic of, Argentina, Spain, Australia, Canada, Russian Federation, United Kingdom, Malaysia, Italy, Poland, Germany, India, Mexico, South Africa
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Anemia | Dialysis

Hong Kong, United States, Singapore, Russian Federation
Kaohsiung Medical University Chung-Ho Memorial...

Completed

A Model of Computer-assisted Prescription of Erythropoiesis-stimulating Agents (ESA) in Patients Under Hemodialysis

End Stage Renal Disease

Taiwan
Protagonist Therapeutics, Inc.

Completed

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia (TRANSCEND)

Chronic Anemia | β-thalassemia | Ineffective Erythropoiesis

United States, Malaysia, Turkey, Thailand, United Kingdom, Italy, Lebanon, Tunisia, Greece
Protagonist Therapeutics, Inc.

Completed

Safety Study for Beta Thalassemia Subjects on PTG-300 (TRANSCEND)

β-thalassemia | Ineffective Erythropoiesis

Malaysia, Thailand, United States, Greece, United Kingdom, Turkey, Lebanon, Tunisia
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Anaemia

Korea, Republic of, Russian Federation, Spain, United States, Australia, United Kingdom, Brazil, Italy, Argentina, Poland, Romania, France, Canada
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

United States, France, Germany
GlaxoSmithKline
Quintiles, Inc.; ERT: Clinical Trial Technology Solutions; Q2 Solutions; HemoCue

Completed

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

Anaemia

United States
Eleos, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Terminated

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States
Akebia Therapeutics

Terminated

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Anemia Associated With Chronic Kidney Disease

United States
Translational Research Center for Medical Innovation...
Niigata University

Completed

Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents (BRIGHTEN)

Chronic Kidney Disease | Renal Anemia

Japan
Esperion Therapeutics, Inc.

Completed

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Diabetes Mellitus, Type 2 | Diabetes | Cholesterolemia

United States
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Chronic Renal Failure With Hemodialysis

China
GlaxoSmithKline

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Anaemia

Spain, United States, Russian Federation, Canada, Germany
Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

Unknown

A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Patient of Anemia in Chronic Renal Failure With Hemodialysis

China
Vifor Fresenius Medical Care Renal Pharma
Worldwide Clinical Trials; Fresenius Medical Care Deutschland GmbH

Terminated

Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial (ANEMEX)

Anemia | End Stage Renal Disease

United Kingdom

Search clinical trials for: Erythropoiesis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations